{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:54:48Z","timestamp":1765382088084,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.07.255","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T21:31:43Z","timestamp":1501795903000},"page":"804-811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"Eskazan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevil","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-0104","authenticated-orcid":false,"given":"Mesut","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Kantarcioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naciye","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demet","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuat","family":"Aydinli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Yokus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isil Erdogan","family":"Ozunal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi Firat","family":"Yalniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugrul","family":"Elverdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse","family":"Salihoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seniz","family":"Ongoren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Baslar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yildiz","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nukhet","family":"Tuzuner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Ozbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teoman","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.07.255_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.07.255_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.255_bib4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.07.255_bib5","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.07.255_bib6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/17474086.2014.966679","article-title":"Generics in chronic myeloid leukemia: current arguments for and against and the established evidence","volume":"7","author":"Soysal","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2017.07.255_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12937","article-title":"First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate","volume":"167","author":"Eskazan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.07.255_bib8","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3109\/10428194.2014.905774","article-title":"The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia","volume":"55","author":"Eskazan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.07.255_bib9","series-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","first-page":"32","article-title":"Chronic myelogenous leukemia BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.clml.2017.07.255_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2017.07.255_bib11","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.255_bib12","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3109\/10428194.2014.904508","article-title":"Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back","volume":"55","author":"Alwan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.07.255_bib13","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3109\/10428194.2014.893302","article-title":"Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety","volume":"55","author":"Saavedra","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"10.1016\/j.clml.2017.07.255_bib14","first-page":"690","article-title":"Generic imatinib mesylate is as effective as original Glivec in the management of CML","volume":"100","author":"Aksu","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.07.255_bib15","first-page":"238","article-title":"EPIC: a phase 3 trial of ponatinib vs imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML)","volume":"99","author":"Chuah","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.07.255_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ejh.12453","article-title":"Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points","volume":"95","author":"Lapusan","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2017.07.255_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11899-017-0375-0","article-title":"The role of early molecular response in\u00a0the management of chronic phase CML","volume":"12","author":"Harrington","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2017.07.255_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.05.009","article-title":"Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: an emerging clinical question","volume":"103","author":"Sweet","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2017.07.255_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2016.06.010","article-title":"Early molecular response in chronic myeloid leukemia and halving time: latest evidences","volume":"48","author":"Breccia","year":"2016","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:34Z","timestamp":1761870574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017309618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017309618"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.255","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}